Asthma in the Yellow Zone
Price: FREE for members and non-members
Session recorded on September 23, 2021
Speaker: Leonard Bacharier, MD
Viewers can earn credit by completing the posttest questions
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary Care Providers
Upon completion of this activity learners should be able to:
1. Identify indications for escalation of asthma therapy in the short term (yellow zone)
2. Develop a yellow zone action plan for patients with asthma of varying severity
3. Discuss relative benefits of various yellow zone strategies
All identified conflicts of interest have been resolved.
Michael Blaiss, MD, Planner
Disclosures: Consultant: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
Leonard Bacharier, MD, Speaker
Disclosures: Consultant: Sanofi, Regeneron, AstraZeneca; Speaker: Sanofi, Regeneron, GSK, Novartis; Advisor Board: Sanofi, Regeneron, GSK, Novartis, AZ, Kinaset
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance